Update on anti-tumor necrosis factor agents and other new drugs for inflammatory bowel disease

BMJ (Online)

Volumn 357, Issue , 2017, Pages

  Cohen, Benjamin L ^a   Sachar, David B ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AGENTS USED IN INFLAMMATORY BOWEL DISEASE; ANTI ATTRACTANT AGENT; ANTI INTERLEUKIN AGENT; ANTIMETABOLITE; AZATHIOPRINE; BIOSIMILAR AGENT; CERTOLIZUMAB PEGOL; FILGOTINIB; FILGRASTIM; GOLIMUMAB; INFLIXIMAB; INFLIXIMAB DYYB; JANUS KINASE INHIBITOR; METHOTREXATE; MONGERSEN; NATALIZUMAB; NEW DRUG; OZANIMOD; TOFACITINIB; TUMOR NECROSIS FACTOR INHIBITOR; UNCLASSIFIED DRUG; UPADACITINIB; USTEKINUMAB; VEDOLIZUMAB; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR;

ALLOPATHY; COLON SURGERY; COMBINATION DRUG THERAPY; CROHN DISEASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MONITORING; DRUG RESEARCH; DRUG RESPONSE; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EVIDENCE BASED PRACTICE; FERTILITY; HUMAN; IMMUNITY; INFECTION; INFLAMMATORY BOWEL DISEASE; MALIGNANT NEOPLASM; MONOTHERAPY; MULTICENTER STUDY (TOPIC); PEROPERATIVE COMPLICATION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSTOPERATIVE PERIOD; PRACTICE GUIDELINE; PREGNANCY; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; REVIEW; SIDE EFFECT; SKIN DEFECT; TREATMENT PLANNING; TREATMENT WITHDRAWAL; ULCERATIVE COLITIS; ANTAGONISTS AND INHIBITORS; GENETIC PREDISPOSITION; INFLAMMATORY BOWEL DISEASES; MOLECULARLY TARGETED THERAPY; TREATMENT OUTCOME; TRENDS; UNITED STATES;

ANTIBODIES, MONOCLONAL; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INFLAMMATORY BOWEL DISEASES; INFLIXIMAB; MOLECULAR TARGETED THERAPY; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; UNITED STATES;

EID: 85021160258     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.j2505     Document Type: Review

References (257)

1. Kappelman MD, Rifas-Shiman SL, Porter CQ, et al. Direct health care costs of Crohn?s disease and ulcerative colitis in US children and adults. Gastroenterology 2008; 135: 1907-13. doi: 10.1053/j.gastro.2008.09.01
2. Loftus EV. Update on the incidence and prevalence of inflammatory bowel disease in the United States. Gastroenterol Hepatol (N Y) 2016; 12: 704-7.
3. Tananthakrishnan AN. Epidemiology and risk factors for IBD. Nat Rev Gastroenterol Hepatol 2015; 12: 205-17. doi: 10.1038/nrgastro.2015.34.
4. McGovern DP, Kugathasan S, Cho JH. Genetics of inflammatory bowel diseases. Gastroenterology 2015; 149: 1163-76.e2. doi: 10.1053/j.gastro.2015.08.001.
5. Ellinghaus D, Bethune J, Petersen BS, et al. The genetics of Crohn?s disease and ulcerative colitis-status quo and beyond. Scand J Gastroenterol 2015; 50: 13-23. doi: 10.3109/00365521.2014.990507.
6. Sachar DB. Appendix redux. Gut 2002; 51: 764-5doi: 10.1136/.gut.51.6.764.
7. Lindberg E, Järnerot G, Huitfeldt B. Smoking in Crohn?s disease: effect on localisation and clinical course. Gut 1992; 33: 779-82doi: 10.1136/.gut.33.6.779.
8. Sachar DB, Walfish A. Inflammatory bowel disease: one or two diseases?. Curr Gastroenterol Rep 2013; 15: 298. doi: 10.1007/s11894-012-0298-9.
9. Côté-Daigneault J, Bouin M, Lahaie R, et al. Biologics in inflammatory bowel disease: what are the data?. United European Gastroenterol J 2015; 3: 419-28. doi: 10.1177/2050640615590302.
10. Amiot A, Peyrin-Biroulet L. Current, new and future biological agents on the horizon for the treatment of inflammatory bowel diseases. Therap Adv Gastroenterol 2015; 8: 66-82. doi: 10.1177/1756283X14558193.
11. Jelsness-Jørgensen LP, Moum B, Bernklev T. Worries and concerns among inflammatory bowel disease patients followed prospectively over one year. Gastroenterology Research and Practice 2011; article 492034. doi: 10.1155/2011/492034
12. Bryant RV, Brain O, Travis SP. Conventional drug therapy for inflammatory bowel disease. Scand J Gastroenterol 2015; 50: 90-112. doi: 10.3109/003 65521.2014.968864.
13. Kornbluth A, Sachar DB. Practice Parameters Committee of the American College of Gastroenterology. Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 2010; 105: 501-23, quiz 24. doi: 10.1038/ajg.2009.727.
14. D?Haens GR, Panaccione R, Higgins PD, et al. The London position statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn?s and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response?. Am J Gastroenterol 2011; 106: 199-212, quiz 13. doi: 10.1038/ajg.2010.392.
15. Gomollón F, Dignass A, Annese V, et al. 3rd European evidence-based consensus on the diagnosis and management of crohn?s disease 2016: Part 1: diagnosis and medical management. J Crohn?s Colitis 2017; 11: 3-25. doi: 10.1093/ecco-jcc/jjw168.
16. Gionchetti P, Dignass A, Danese S, et al. 3. EUROPEAN Evidence-based consensus on the diagnosis and management of Crohn?s disease 2016: Part 2: Surgical managemenTand special situations. J Crohn?s Colitis 2017; 11: 135-49. doi: 10.1093/ecco-jcc/jjw169.
17. Harbord M, Eliakim R, Bettenworth D, et al. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2: current management. J Crohn?s Colitis 2017; jjx009. doi: 10.1093/ecco-jcc/jjx009.
18. Farraye FA, Melmed GY, Lichtenstein GR, et al. ACG clinical guideline: preventive care in inflammatory bowel disease. Am J Gastroenterol 2017; 112: 241-58. doi: 10.1038/ajg.2016.537.
19. Velayos FS, Sandborn WJ. Positioning biologic therapy for Crohn?s disease and ulcerative colitis. Curr Gastroenterol Rep 2007; 9: 521-7doi: 10.1007/.s11894-007-0069-1.
20. Fernandes C, Allocca M, Danese S, et al. Progress with anti-Tumor necrosis factor therapeutics for the treatment of inflammatory bowel disease. Immunotherapy 2015; 7: 175-90. doi: 10.2217/imt.14.105.
21. Lopez A, Ford AC, Colombel JF, et al. Efficacy of tumour necrosis factor antagonists on remission, colectomy and hospitalisations in ulcerative colitis: Meta-Analysis of placebo-controlled trials. Dig Liver Dis 2015; 47: 356-64. doi: 10.1016/j.dld.2015.01.148.
22. Torres J, Billioud V, Sachar DB, et al. Ulcerative colitis as a progressive disease: the forgotten evidence. Inflamm Bowel Dis 2012; 18: 1356-63. doi: 10.1002/ibd.22839.
23. Bálint A, Farkas K, Palatka K, et al. Efficacy and safety of adalimumab in ulcerative colitis refractory to conventional therapy in routine clinical practice. J Crohn?s Colitis 2016; 10: 26-30. doi: 10.1093/ecco-jcc/jjv169.
24. Mei WQ, Hu HZ, Liu Y, et al. Infliximab is superior to other biological agents for treatment of active ulcerative colitis: a meta-Analysis. World J Gastroenterol 2015; 21: 6044-51et al3748/wjg.v21.i19.6044.
25. Thorlund K, Druyts E, Mills EJ, et al. Adalimumab versus infliximab for the treatment of moderate to severe ulcerative colitis in adult patients naïve to anti-TNF therapy: an indirect treatment comparison meta-Analysis. J Crohn?s Colitis 2014; 8: 571-81. doi: 10.1016/j.crohns.2014.01.010.
26. Thorlund K, Druyts E, Toor K, et al. Comparative efficacy of golimumab, infliximab, and adalimumab for moderately to severely active ulcerative colitis: a network meta-Analysis accounting for differences in trial designs. Expert Rev Gastroenterol Hepatol 2015; 9: 693-700. doi: 10.1586/174741 24.2015.1024657.
27. Tananthakrishnan AN, Cagan A, Cai T, et al. Comparative effectiveness of infliximab and adalimumab in Crohn?s disease and ulcerative colitis. Inflamm Bowel Dis 2016; 22: 880-5. doi: 10.1097/MIB.0000000000000754.
28. Sandborn WJ, Sakuraba A, Wang A, et al. Comparison of real-world outcomes of adalimumab and infliximab for patients with ulcerative colitis in the United States. Curr Med Res Opin 2016; 32: 1233-4. doi: 10.1185/03007995.20 16.1168290.
29. Singh S, Heien HC, Sangaralingham LR, et al. Comparative effectiveness and safety of anti-Tumor necrosis factor agents in biologic-naive patients with Crohn?s disease. Clin Gastroenterol Hepatol 2016; 14: 1120-29.e6. doi: 10.1016/j.cgh.2016.03.038.
30. Hanauer SB. Crohn?s disease: step up or top down therapy. Best Pract Res Clin Gastroenterol 2003; 17: 131-7doi: 10.1053/bega.2003.0361.
31. Rogler G. Top-down or step-up treatment in Crohn?s disease?. Dig Dis 2013; 31: 83-90. doi: 10.1159/000347190.
32. Lee YM, Kang B, Lee Y, et al. Infliximab top-down strategy is superior to step-up in maintaining long-Term remission in the treatment of pediatric Crohn disease. J Pediatr Gastroenterol Nutr 2015; 60: 737-43. doi: 10.1097/.MPG.0000000000000711.
33. Marchetti M, Liberato NL, Di Sabatino A, et al. Cost-effectiveness analysis of top-down versus step-up strategies in patients with newly diagnosed active luminal Crohn?s disease. Eur J Health Econ 2013; 14: 853-61. doi: 10.1007/.s10198-012-0430-7.
34. Ghazi LJ, Patil SA, Rustgi A, et al. Step up versus early biologic therapy for Crohn?s disease in clinical practice. Inflamm Bowel Dis 2013; 19: 1397-403. doi: 10.1097/MIB.0b013e318281337d.
35. Ma C, Beilman CL, Huang VW, et al. Anti-TNF therapy within 2 years of Crohn?s disease diagnosis improves patient outcomes: a retrospective cohort study. Inflamm Bowel Dis 2016; 22: 870-9. doi: 10.1097/.MIB.0000000000000679.
36. Schreiber S, Reinisch W, Colombel JF, et al. Subgroup analysis of the placebo-controlled CHARM trial: increased remission rates through 3 years for adalimumab-Treated patients with early Crohn?s disease. J Crohn?s Colitis 2013; 7: 213-21. doi: 10.1016/j.crohns.2012.05.015.
37. Rubin DT, Uluscu O, Sederman R. Response to biologic therapy in Crohn?s disease is improved with early treatment: an analysis of health claims data. Inflamm Bowel Dis 2012; 18: 2225-31. doi: 10.1002/ibd.22925.
38. Olbjørn C, Nakstad B, Småstuen MC, et al. Early anti-TNF treatment in pediatric Crohn?s disease. Predictors of clinical outcome in a population-based cohort of newly diagnosed patients. Scand J Gastroenterol 2014; 49: 1425-31. doi: 10.3109/00365521.2014.966316.
39. Wenger S, Nikolaus S, Howaldt S, et al. Predictors for subsequent need for immunosuppressive therapy in early Crohn?s disease. J Crohn?s Colitis 2012; 6: 21-8. doi: 10.1016/j.crohns.2011.06.006.
40. Karoui S, Serghini M, Dachraoui A, et al. Prognostic factors in Crohn?s disease: a systematic review. Tunis Med 2013; 91: 230-3.
41. Benitez JM, Louis E. Can we predict the high-risk patient?. Dig Dis 2014; 32: 328-36. doi: 10.1159/000358132.
42. Papp M, Lakatos PL. Serological studies in inflammatory bowel disease: how important are they?. Curr Opin Gastroenterol 2014; 30: 359-64. doi: 10.1097/MOG.0000000000000076.
43. Kovács M, Müller KE, Papp M, et al. New serological markers in pediatric patients with inflammatory bowel disease. World J Gastroenterol 2014; 20: 4873-82. doi: 10.3748/wjg.v20.i17.4873.
44. Onali S, Calabrese E, Petruzziello C, et al. Post-operative recurrence of Crohn?s disease: a prospective study at 5 years. Dig Liver Dis 2016; 48: 489-94. doi: 10.1016/j.dld.2016.01.009.
45. Sorrentino D, Terrosu G, Avellini C, et al. Prevention of postoperative recurrence of Crohn?s disease by infliximab. Eur J Gastroenterol Hepatol 2006; 18: 457-9doi: 10.1097/00042737-200604000-00025.
46. Regueiro M, Schraut W, Baidoo L, et alInfliximab prevents Crohn's disease recurrence after ileal resection. Gastroenterology 2009; 136(2): 441-50.e1; quiz 716. doi: 10.1053/j.gastro.2008.10.051
47. Regueiro M, Kip KE, Baidoo L, et al. Postoperative therapy with infliximab prevents long-Term Crohn?s disease recurrence. Clin Gastroenterol Hepatol 2014; 12: 1494-502.e1. doi: 10.1016/j.cgh.2013.12.035.
48. Sartor RB. Preventing postoperative recurrence of Crohn?s disease: how can we improve results?. Clin Gastroenterol Hepatol 2015; 13: 936-9. doi: 10.1016/j.cgh.2014.12.027.
49. Carla-Moreau A, Paul S, Roblin X, et al. Prevention and treatment of postoperative Crohn?s disease recurrence with anti-TNF therapy: a meta-Analysis of controlled trials. Dig Liver Dis 2015; 47: 191-6. doi: 10.1016/j.dld.2014.11.005.
50. Singh S, Garg SK, Pardi DS, et alComparative efficacy of pharmacologic interventions in preventing relapse of Crohn's disease after surgery: a systematic review and network meta-Analysis. Gastroenterology2015; 148(1): 64-76.e2; quiz e14. doi: 10.1053/j.gastro.2014.09.031
51. Savarino E, Bodini G, Dulbecco P, et al. Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn?s disease: a randomized controlled trial. Am J Gastroenterol 2013; 108: 1731-42. doi: 10.1038/ajg.2013.287.
52. Vaughn BP, Moss AC. Prevention of post-operative recurrence of Crohn?s disease. World J Gastroenterol 2014; 20: 1147-54. doi: 10.3748/wjg.v20. i5.1147.
53. Araki T, Uchida K, Okita Y, et al. Impact of postoperative infliximab maintenance therapy on preventing the surgical recurrence of Crohn?s disease: a single-center paired case-control study. Surg Today 2014; 44: 291-6. doi: 10.1007/s00595-013-0538-0.
54. Kotze PG, Yamamoto T, Danese S, et al. Direct retrospective comparison of adalimumab and infliximab in preventing early postoperative endoscopic recurrence after ileocaecal resection for crohn?s disease: results from the MULTIPER database. J Crohn?s Colitis 2015; 9: 541-7. doi: 10.1093/ecco-jcc/.jjv055.
55. Sakuraba A, Okamoto S, Matsuoka K, et al. Combination therapy with infliximab and thiopurine compared to infliximab monotherapy in maintaining remission of postoperative Crohn?s disease. Digestion 2015; 91: 233-8. doi: 10.1159/000375302.
56. Kamm MA, De Cruz PP, Wright EK, et al. Optimising post-operative Crohn?s disease management: best drug therapy alone versus endoscopic monitoring, disease evolution, and faecal calprotectin monitoring. The POCER study. J Crohn?s Colitis 2014; 8: S13. doi: 10.1016/s1873-9946(14)60024-6.
57. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn?s disease. N Engl J Med 2010; 362: 1383-95. doi: 10.1056/NEJMoa0904492.
58. De Cruz P, Kamm MA, Hamilton AL, et al. Crohn?s disease management after intestinal resection: a randomised trial. Lancet 2015; 385: 1406-17. doi: 10.1016/S0140-6736(14)61908-5.
59. Ferrante M, Papamichael K, Duricova D, et al. Systematic versus endoscopy-driven treatment with azathioprine to prevent postoperative ileal Crohn?s disease recurrence. J Crohn?s Colitis 2015; 9: 617-24. doi: 10.1093/ecco-jcc/.jjv076.
60. Kotze PG, Yamamoto T, Damião AO. Postoperative approach for Crohn?s disease: the right therapy to the right patient. Curr Drug Targets 2015doi: 10. 2174/1389450116666151102094922
61. Fornaro R, Caratto E, Caratto M, et al. Post-operative recurrence in Crohn?s disease. Critical analysis of potential risk factors. An update. Surgeon 2015; 13: 330-47. doi: 10.1016/j.surge.2015.04.002.
62. Morar PS, Faiz O, Hodgkinson JD, et al. Concomitant colonic disease (Montreal L3) and re-resectional surgery are predictors of clinical recurrence following ileocolonic resection for Crohn?s disease. Colorectal Dis 2015; 17: 247-55. doi: 10.1111/codi.13094.
63. Han YM, Kim JW, Koh SJ, et al. Patients with perianal Crohn?s disease have poor disease outcomes after primary bowel resection. J Gastroenterol Hepatol 2016; 31: 1436-42. doi: 10.1111/jgh.13310.
64. Cabré E, Domènech E. Impact of environmental and dietary factors on the course of inflammatory bowel disease. World J Gastroenterol 2012; 18: 3814-22. doi: 10.3748/wjg.v18.i29.3814.
65. Yamamoto T, Watanabe T. Strategies for the prevention of postoperative recurrence of Crohn?s disease. Colorectal Dis 2013; 15: 1471-80. doi: 10.1111/codi.12326.
66. Buisson A, Chevaux JB, Allen PB, et al. Review article: the natural history of postoperative Crohn?s disease recurrence. Aliment Pharmacol Ther 2012; 35: 625-33. doi: 10.1111/j.1365-2036.2012.05002.x.
67. Panaccione R, Ghosh S, Middleton S, et al. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology 2014; 146: 392-400.e3. doi: 10.1053/j.gastro.2013.10.052.
68. Khanna R, Bressler B, Levesque BG, et al. Early combined immunosuppression for the management of Crohn?s disease (REACT): a cluster randomised controlled trial. Lancet 2015; 386: 1825-34. doi: 10.1016/S0140-6736(15)00068-9.
69. Cross RK. Which patients with inflammatory bowel disease should receive combination therapy?. Expert Rev Gastroenterol Hepatol 2015; 9: 715-7. doi: 10.1586/17474124.2015.1039989.
70. Vaysse T, Carbonnel F. Methotrexate in IBD: the return of the prodigal son. J Crohn?s Colitis 2015; 9: 303-4. doi: 10.1093/ecco-jcc/jjv038.
71. Ward MG, Irving PM, Sparrow MP. How should immunomodulators be optimized when used as combination therapy with anti-Tumor necrosis factor agents in the management of inflammatory bowel disease?. World J Gastroenterol 2015; 21: 11331-42. doi: 10.3748/wjg.v21.i40.11331.
72. Dulai PS, Siegel CA, Colombel JF, et al. Systematic review: monotherapy with antitumour necrosis factor α agents versus combination therapy with an immunosuppressive for IBD. Gut 2014; 63: 1843-53. doi: 10.1136/.gutjnl-2014-307126.
73. Feagan BG, McDonald JW, Panaccione R, et al. Methotrexate in combination with infliximab is no more effective than infliximab alone in patients with Crohn?s disease. Gastroenterology 2014; 146: 681-88.e1. doi: 10.1053/j.gastro.2013.11.024.
74. Carbonnel F, Colombel JF, Filippi J, et al. Methotrexate is not superior to placebo for inducing steroid-free remission, but induces steroid-free clinical remission in a larger proportion of patients with ulcerative colitis. Gastroenterology 2016; 150: 380-8.e4. doi: 10.1053/j.gastro.2015.10.050.
75. Oren R, Arber N, Odes S, et al. Methotrexate in chronic active ulcerative colitis: a double-blind, randomized, Israeli multicenter trial. Gastroenterology 1996; 110: 1416-21doi: 10.1053/gast.1996.v110.pm8613046.
76. Kurnik D, Loebstein R, Fishbein E, et al. Bioavailability of oral v subcutaneous low-dose methotrexate in patients with Crohn?s disease. Aliment Pharmacol Ther 2003; 18: 57-63doi: 10.1046/j.1365-2036.2003.01614.x.
77. Herfarth HH, Kappelman MD, Long MD, et al. Use of methotrexate in the treatment of inflammatory bowel diseases. Inflamm Bowel Dis 2016; 22: 224-33. doi: 10.1097/MIB.0000000000000589.
78. Jones JL, Kaplan GG, Peyrin-Biroulet L, et alEffects of concomitant immunomodulator therapy on efficacy and safety of anti-Tumor necrosis factor therapy for Crohn's disease: a meta-Analysis of placebo-controlled trials. Clin Gastroenterol Hepatol 2015; 13(13): 2233-40.e1-2; quiz e177-8. doi: 10.1016/j.cgh.2015.06.034
79. Ben-Horin S, Waterman M, Kopylov U, et al. Addition of an immunomodulator to infliximab therapy eliminates antidrug antibodies in serum and restores clinical response of patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2013; 11: 444-7. doi: 10.1016/j.cgh.2012.10.020.
80. Sandborn WJ, Feagan BG, Marano C, et al. Subcutaneous golimumab maintains clinical response in patients with moderate-To-severe ulcerative colitis. Gastroenterology 2014; 146: 96-109.e1. doi: 10.1053/j.gastro.2013.06.010.
81. Yarur AJ, Jain A, Hauenstein SI, et al. Higher adalimumab levels are associated with histologic and endoscopic remission in patients with Crohn?s disease and ulcerative colitis. Inflamm Bowel Dis 2016; 22: 409-15. doi: 10.1097/.MIB.0000000000000689.
82. Vermeire S, Noman M, Van Assche G, et al. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn?s disease. Gut 2007; 56: 1226-31. doi: 10.1136/.gut.2006.099978.
83. Chiu YL, Rubin DT, Vermeire S, et al. Serum adalimumab concentration and clinical remission in patients with Crohn?s disease. Inflamm Bowel Dis 2013; 19: 1112-22. doi: 10.1097/MIB.0b013e3182813242.
84. Karmiris K, Paintaud G, Noman M, et al. Influence of trough serum levels and immunogenicity on long-Term outcome of adalimumab therapy in Crohn?s disease. Gastroenterology 2009; 137: 1628-40. doi: 10.1053/j.gastro.2009.07.062.
85. van Schaik T, Maljaars JP, Roopram RK, et al. Influence of combination therapy with immune modulators on anti-TNF trough levels and antibodies in patients with IBD. Inflamm Bowel Dis 2014; 20: 2292-8. doi: 10.1097/.MIB.0000000000000208.
86. Bond A, Dodd S, Fisher G, et al. Concurrent immunomodulator therapy is associated with higher adalimumab trough levels during scheduled maintenance therapy. Scand J Gastroenterol 2016; 1-5. doi: 10.1080/0036 5521.2016.1245777.
87. Schreiber S, Khaliq-Kareemi M, Lawrance IC, et al. Maintenance therapy with certolizumab pegol for Crohn?s disease. N Engl J Med 2007; 357: 239-50. doi: 10.1056/NEJMoa062897.
88. Bortlik M, Duricova D, Malickova K, et al. Infliximab trough levels may predict sustained response to infliximab in patients with Crohn?s disease. J Crohn?s Colitis 2013; 7: 736-43. doi: 10.1016/j.crohns.2012.10.019.
89. Vande Casteele N, Gils A, Singh S, et al. Antibody response to infliximab and its impact on pharmacokinetics can be transient. Am J Gastroenterol 2013; 108: 962-71. doi: 10.1038/ajg.2013.12.
90. Cornillie F, Hanauer SB, Diamond RH, et al. Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial. Gut 2014; 63: 1721-7. doi: 10.1136/gutjnl-2012-304094.
91. Ungar B, Chowers Y, Yavzori M, et al. The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab. Gut 2014; 63: 1258-64. doi: 10.1136/gutjnl-2013-305259.
92. Kotlyar DS, Osterman MT, Diamond RH, et al. A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2011; 9: 36-41.e1. doi: 10.1016/j.cgh.2010.09.016.
93. Beaugerie L. Lymphoma: the bête noire of the long-Term use of thiopurines in adulTand elderly patients with inflammatory bowel disease. Gastroenterology 2013; 145: 927-30. doi: 10.1053/j.gastro.2013.09.035.
94. Cesarini M, Festa S, Papi C. Methotrexate in Crohn?s disease: a new face for an old drug?. Expert Rev Gastroenterol Hepatol 2016. doi: 10.1080/174741 24.2016.1185363.
95. Setshedi M, Epstein D, Winter TA, et al. Use of thiopurines in the treatment of inflammatory bowel disease is associated with an increased risk of non-melanoma skin cancer in an at-risk population: a cohort study. J Gastroenterol Hepatol 2012; 27: 385-9. doi: 10.1111/j.1440-1746.2011.06865.x.
96. Peyrin-Biroulet L, Khosrotehrani K, Carrat F, et alIncreased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease. Gastroenterology 2011; 141(5): 1621-28. e1-5. doi: 10.1053/j.gastro.2011.06.050
97. Ariyaratnam J, Subramanian V. Association between thiopurine use and nonmelanoma skin cancers in patients with inflammatory bowel disease: a meta-Analysis. Am J Gastroenterol 2014; 109: 163-9. doi: 10.1038/.ajg.2013.451.
98. Cottone M, Kohn A, Daperno M, et al. Advanced age is an independent risk factor for severe infections and mortality in patients given anti-Tumor necrosis factor therapy for inflammatory bowel disease. Clin Gastroenterol Hepatol 2011; 9: 30-5. doi: 10.1016/j.cgh.2010.09.026.
99. Lobatón T, Ferrante M, Rutgeerts P, et al. Efficacy and safety of anti-TNF therapy in elderly patients with inflammatory bowel disease. Aliment Pharmacol Ther 2015; 42: 441-51. doi: 10.1111/apt.13294.
100. Best WR, Becktel JM, Singleton JW, et al. Development of a Crohn?s disease activity index. National Cooperative Crohn?s Disease Study. Gastroenterology 1976; 70: 439-44.
101. Sands BE, Ooi CJ. A survey of methodological variation in the Crohn?s disease activity index. Inflamm Bowel Dis 2005; 11: 133-8doi: 10.1097/00054725-200502000-00006.
102. Thia K, Faubion WA, Loftus EV, et al. Short CDAI: developmenTand validation of a shortened and simplified Crohn?s disease activity index. Inflamm Bowel Dis 2011; 17: 105-11. doi: 10.1002/ibd.21400.
103. Khanna R, Zou G, D?Haens G, et al. A retrospective analysis: the development of patient reported outcome measures for the assessment of Crohn?s disease activity. Aliment Pharmacol Ther 2015; 41: 77-86. doi: 10.1111/.apt.13001.
104. Cellier C, Sahmoud T, Froguel E, et al. Correlations between clinical activity, endoscopic severity, and biological parameters in colonic or ileocolonic Crohns-disease-A prospective multicenter study of 121 cases. Gut 1994; 35: 231-5. doi: 10.1136/gut.35.2.231.
105. Regueiro M, Kip KE, Schraut W, et al. Crohn?s disease activity index does not correlate with endoscopic recurrence one year after ileocolonic resection. Inflamm Bowel Dis 2011; 17: 118-26. doi: 10.1002/ibd.21355.
106. Papay P, Ignjatovic A, Karmiris K, et al. Optimising monitoring in the management of Crohn?s disease: a physician?s perspective. J Crohn?s Colitis 2013; 7: 653-69. doi: 10.1016/j.crohns.2013.02.005.
107. Sostegni R, Daperno M, Scaglione N, et al. Review article: Crohn?s disease: monitoring disease activity. Aliment Pharmacol Ther 2003; 17(Suppl 2): 11-7doi: 10.1046/j.1365-2036.17.s2.17.x.
108. Sandborn WJ, Hanauer S, Van Assche G, et al. Treating beyond symptoms with a view to improving patient outcomes in inflammatory bowel diseases. J Crohn?s Colitis 2014; 8: 927-35. doi: 10.1016/j.crohns.2014.02.021.
109. Lewis JD. The utility of biomarkers in the diagnosis and therapy of inflammatory bowel disease. Gastroenterology 2011; 140: 1817-26.e2. doi: 10.1053/j.gastro.2010.11.058.
110. Sachar DB. IOIBD BTFot. Role of biomarkers in the study and management of inflammatory bowel disease: a nonsystematic review. Inflamm Bowel Dis 2014; 20: 2511-8. doi: 10.1097/MIB.0000000000000135.
111. Hordonneau C, Buisson A, Scanzi J, et al. Diffusion-weighted magnetic resonance imaging in ileocolonic Crohn?s disease: validation of quantitative index of activity. Am J Gastroenterol 2014; 109: 89-98. doi: 10.1038/.ajg.2013.385.
112. Pariente B, Mary JY, Danese S, et al. Development of the Lémann index to assess digestive tract damage in patients with Crohn?s disease. Gastroenterology 2015; 148: 52-63.e3. doi: 10.1053/j.gastro.2014.09.015.
113. Reinink AR, Lee TC, Higgins PD. Endoscopic mucosal healing predicts favorable clinical outcomes in inflammatory bowel disease: a meta-Analysis. Inflamm Bowel Dis 2016; 22: 1859-69. doi: 10.1097/.MIB.0000000000000816.
114. Papamichael K, Van Stappen T, Vande Casteele N, et al. Infliximab concentration thresholds during induction therapy are associated with short-Term mucosal healing in patients with ulcerative colitis. Clin Gastroenterol Hepatol 2016; 14: 543-9. doi: 10.1016/j.cgh.2015.11.014.
115. Ungar B, Levy I, Yavne Y, et al. Optimizing anti-TNF-α therapy: serum levels of infliximab and adalimumab are associated with mucosal healing in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol 2016; 14: 550-57.e2. doi: 10.1016/j.cgh.2015.10.025.
116. Peyrin-Biroulet L, Sandborn W, Sands BE, et al. Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-To-Target. Am J Gastroenterol 2015; 110: 1324-38. doi: 10.1038/.ajg.2015.233.
117. Sands BE. Biomarkers of inflammation in inflammatory bowel disease. Gastroenterology 2015; 149: 1275-85.e2. doi: 10.1053/j.gastro.2015.07.003.
118. Lewis JD. The utility of biomarkers in the diagnosis and therapy of inflammatory bowel disease. Gastroenterology 2011; 140: 1817-26.e2. doi: 10.1053/j.gastro.2010.11.058
119. Torres J, Boyapati RK, Kennedy NA, et al. Systematic review of effects of withdrawal of immunomodulators or biologic agents from patients with inflammatory bowel disease. Gastroenterology 2015; 149: 1716-30. doi: 10.1053/j.gastro.2015.08.055.
120. Gisbert JP, Marín AC, Chaparro M. The risk of relapse after anti-TNF discontinuation in inflammatory bowel disease: systematic review and meta-Analysis. Am J Gastroenterol 2016; 111: 632-47. doi: 10.1038/ajg.2016.54.
121. Lau C, Dubinsky M, Melmed G, et al. The impact of preoperative serum anti-TNFα therapy levels on early postoperative outcomes in inflammatory bowel disease surgery. Ann Surg 2015; 261: 487-96. doi: 10.1097/.SLA.0000000000000757.
122. Van Assche G, Magdelaine-Beuzelin C, D?Haens G, et al. Withdrawal of immunosuppression in Crohn?s disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology 2008; 134: 1861-8. doi: 10.1053/j.gastro.2008.03.004.
123. Sokol H, Seksik P, Nion-Larmurier I, et al. Withdrawal of immunosuppression in inflammatory bowel disease treated with infliximab maintenance therapy. Gastroenterology 2009; 136: A187-88doi: 10.1016/S0016-5085(09)60844-1.
124. Drobne D, Bossuyt P, Breynaert C, et al. Withdrawal of immunomodulators after co-Treatment does not reduce trough level of infliximab in patients with Crohn?s disease. Clin Gastroenterol Hepatol 2015; 13: 514-21. doi: 10.1016/j.cgh.2014.07.027.
125. Choi GJ, Park DI, Park JH, et al. Withdrawal of azathioprine in luminal Crohn?s disease treated with infliximab maintenance therapy: a retrospective case-control study. J Gastroenterol Hepatol 2010; 25: A86-86.
126. Fischer M, Campbell SC, Johnson CS, et al. Risk factors for rescue therapy in Crohn?s patients on combination therapy after discontinuation of the immunomodulator. Gastroenterology 2014; 146: S450-50doi: 10.1016/.S0016-5085(14)61616-4.
127. Oussalah A, Chevaux JB, Fay R, et al. Predictors of infliximab failure after azathioprine withdrawal in Crohn?s disease treated with combination therapy. Am J Gastroenterol 2010; 105: 1142-9. doi: 10.1038/.ajg.2010.158.
128. Filippi J, Laharie D, Michiels C, et al. Efficacy of sustained combination therapy for at least 6 months with thiopurines and infliximab in patients with ulcerative colitis in clinical remission: a retrospective multicenter French experience. J Crohn?s Colitis 2015; 9: 252-8. doi: 10.1093/ecco-jcc/jjv001.
129. Dubinsky MC, Lamothe S, Yang HY, et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000; 118: 705-13doi: 10.1016/S0016-5085(00)70140-5.
130. Yarur AJ, Kubiliun MJ, Czul F, et al. Concentrations of 6-Thioguanine nucleotide correlate with trough levels of infliximab in patients with inflammatory bowel disease on combination therapy. Clin Gastroenterol Hepatol 2015; 13: 1118-24.e3. doi: 10.1016/j.cgh.2014.12.026.
131. Colman RJ, Rubin DT. Optimal doses of methotrexate combined with anti-TNF therapy to maintain clinical remission in inflammatory bowel disease. J Crohn?s Colitis 2015; 9: 312-7. doi: 10.1093/ecco-jcc/jjv027.
132. Papamichael K, Vande Casteele N, Gils A, et al. Long-Term outcome of patients with Crohn?s disease who discontinued infliximab therapy upon clinical remission. Clin Gastroenterol Hepatol 2015; 13: 1103-10. doi: 10.1016/j.cgh.2014.11.026.
133. Molnár T, Lakatos PL, Farkas K, et al. Predictors of relapse in patients with Crohn?s disease in remission after 1 year of biological therapy. Aliment Pharmacol Ther 2013; 37: 225-33. doi: 10.1111/apt.12160.
134. Louis E, Mary JY, Vernier-Massouille G, et alMaintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped. Gastroenterology 2012; 142(1): 63-70.e5; quiz e31. doi: 10.1053/j.gastro.2011.09.034
135. de Suray N, Salleron J, Vernier-Massouille G, et al. Close monitoring of CRP and fecal calprotectin is able to predict clinical relapse in patients with Crohn?s disease in remission after infliximab withdrawal. a sub-Analysis of the Stori Study. Gastroenterology 2012; 142: S149-49doi: 10.1016/S0016-5085(12)60560-5.
136. Brooks AJ, Sebastian S, Cross SS, et al. Outcome of elective withdrawal of anti-Tumour necrosis factor-α therapy in patients with Crohn?s disease in established remission. J Crohn?s Colitis 2015. doi: 10.1016/j.crohns.2014.09.007.
137. Bortlik M, Duricova D, Machkova N, et al. Discontinuation of anti-Tumor necrosis factor therapy in inflammatory bowel disease patients: a prospective observation. Scand J Gastroenterol 2016; 51: 196-202. doi: 10. 3109/00365521.2015.1079924.
138. Gisbert JP, Marín AC, Chaparro M. Systematic review: factors associated with relapse of inflammatory bowel disease after discontinuation of anti-TNF therapy. Aliment Pharmacol Ther 2015; 42: 391-405. doi: 10.1111/.apt.13276.
139. Casanova MJ, Chaparro M, García-Sánchez V, et al. Evolution after anti-TNF discontinuation in patients with inflammatory bowel disease: a multicenter long-Term follow-up study. Am J Gastroenterol 2017; 112: 120-31. doi: 10.1038/ajg.2016.569.
140. Molander P, Färkkilä M, Ristimäki A, et al. Does fecal calprotectin predict short-Term relapse after stopping TNFα-blocking agents in inflammatory bowel disease patients in deep remission?. J Crohn?s Colitis 2015; 9: 33-40. doi: 10.1016/j.crohns.2014.06.012.
141. Vande Casteele N, Ferrante M, Van Assche G, et al. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease. Gastroenterology 2015; 148: 1320-9.e3. doi: 10.1053/j.gastro.2015.02.031.
142. Duron C, Goutte M, Pereira B, et al. Factors influencing acute infusion reactions in inflammatory bowel disease patients treated with infliximab in the era of scheduled maintenance therapy. Eur J Gastroenterol Hepatol 2015; 27: 705-11. doi: 10.1097/MEG.0000000000000354.
143. Baert F, Drobne D, Gils A, et alEarly trough levels and antibodies to infliximab predict safety and success of reinitiation of infliximab therapy. Clin Gastroenterol Hepatol 2014; 12(9): 1474-81.e2; quiz e91. doi: 10.1016/j.cgh.2014.01.033
144. Ben-Horin S, Mazor Y, Yanai H, et al. The decline of anti-drug antibody titres after discontinuation of anti-TNFs: implications for predicting re-induction outcome in IBD. Aliment Pharmacol Ther 2012; 35: 714-22. doi: 10.1111/.j.1365-2036.2012.04997.x.
145. Ford AC, Sandborn WJ, Khan KJ, et al. Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-Analysis. Am J Gastroenterol 2011; 106: 644-59, quiz 60. doi: 10.1038/ajg.2011.73.
146. Gisbert JP, Panés J. Loss of response and requirement of infliximab dose intensification in Crohn?s disease: a review. Am J Gastroenterol 2009; 104: 760-7. doi: 10.1038/ajg.2008.88.
147. Billioud V, Sandborn WJ, Peyrin-Biroulet L. Loss of response and need for adalimumab dose intensification in Crohn?s disease: a systematic review. Am J Gastroenterol 2011; 106: 674-84. doi: 10.1038/ajg.2011.60.
148. Singh N, Dubinsky MC. Therapeutic drug monitoring in children and young adults with inflammatory bowel disease: a practical approach. Gastroenterol Hepatol (N Y) 2015; 11: 48-55.
149. Sandborn WJ, Rutgeerts P, Enns R, et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med 2007; 146: 829-38doi: 10.7326/0003-4819-146-12-200706190-00159.
150. Sandborn WJ, Abreu MT, D?Haens G, et al. Certolizumab pegol in patients with moderate to severe Crohn?s disease and secondary failure to infliximab. Clin Gastroenterol Hepatol 2010; 8: 688-95.e2. doi: 10.1016/j.cgh.2010.04.021.
151. Steenholdt C, Bendtzen K, Brynskov J, et al. Optimizing treatment with TNF inhibitors in inflammatory bowel disease by monitoring drug levels and antidrug antibodies. Inflamm Bowel Dis 2016; 22: 1999-2015. doi: 10.1097/MIB.0000000000000772.
152. Gils A, Vande Casteele N, Poppe R, et al. Development of a universal anti-Adalimumab antibody standard for interlaboratory harmonization. Ther Drug Monit 2014; 36: 669-73. doi: 10.1097/FTD.0000000000000074.
153. Steenholdt C, Frederiksen MT, Bendtzen K, et al. Time course and clinical implications of development of antibodies against adalimumab in patients with inflammatory bowel disease. J Clin Gastroenterol 2016; 50: 483-9. doi: 10.1097/MCG.0000000000000375.
154. Steenholdt C, Bendtzen K, Brynskov J, et al. Changes in serum trough levels of infliximab during treatment intensification but not in anti-infliximab antibody detection are associated with clinical outcomes after therapeutic failure in Crohn?s disease. J Crohn?s Colitis 2015; 9: 238-45. doi: 10.1093/ecco-jcc/.jjv004.
155. Seow CH, Newman A, Irwin SP, et al. Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis. Gut 2010; 59: 49-54. doi: 10.1136/gut.2009.183095.
156. Steenholdt C, Al-khalaf M, Brynskov J, et al. Clinical implications of variations in anti-infliximab antibody levels in patients with inflammatory bowel disease. Inflamm Bowel Dis 2012; 18: 2209-17. doi: 10.1002/ibd.22910.
157. Ungar B, Kopylov U, Engel T, et al. Addition of an immunomodulator can reverse antibody formation and loss of response in patients treated with adalimumab. Aliment Pharmacol Ther 2016; 45: 276-82. doi: 10.1111/.apt.13862.
158. Ong DE, Kamm MA, Hartono JL, et al. Addition of thiopurines can recapture response in patients with Crohn?s disease who have lost response to anti-Tumor necrosis factor monotherapy. J Gastroenterol Hepatol 2013; 28: 1595-9. doi: 10.1111/jgh.12263.
159. Papamichael K, Karatzas P, Mantzaris GJ. Addition of an immunomodulator as a rescue therapy for loss of response to adalimumab dose escalation in patients with Crohn?s disease. J Crohn?s Colitis 2015; 9: 589-90. doi: 10.1093/ecco-jcc/jjv062.
160. Velayos FS, Kahn JG, Sandborn WJ, et al. A test-based strategy is more cost effective than empiric dose escalation for patients with Crohn?s disease who lose responsiveness to infliximab. Clin Gastroenterol Hepatol 2013; 11: 654-66. doi: 10.1016/j.cgh.2012.12.035.
161. Afif W, Loftus EV, Faubion WA, et al. Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol 2010; 105: 1133-9. doi: 10.1038/.ajg.2010.9.
162. Yanai H, Lichtenstein L, Assa A, et al. Levels of drug and antidrug antibodies are associated with outcome of interventions after loss of response to infliximab or adalimumab. Clin Gastroenterol Hepatol 2015; 13: 522-30.e2. doi: 10.1016/j.cgh.2014.07.029.
163. Steenholdt C, Brynskov J, Thomsen O, et al. Individualised therapy is more cost-effective than dose intensification in patients with Crohn?s disease who lose response to anti-TNF treatment: a randomised, controlled trial. Gut 2014; 63: 919-27. doi: 10.1136/gutjnl-2013-305279.
164. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353: 2462-76doi: 10.1056/NEJMoa050516.
165. Sandborn WJ, Rutgeerts P, Feagan BG, et al. Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology 2009; 137: 1250-60, quiz 520. doi: 10.1053/j.gastro.2009.06.061.
166. Sands BE, Tremaine WJ, Sandborn WJ, et al. Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study. Inflamm Bowel Dis 2001; 7: 83-8doi: 10.1097/00054725-200105000-00001.
167. Jarnerot G, Hertervig E, Friis-Liby I, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 2005; 128: 1805-11. doi: 10.1053/j.gastro.2005.03.003.
168. Sjoberg M, Almer S, Befrits R, et al. Infliximab as rescue therapy in steroid-refractory acute ulcerative colitis; a retrospective follow-up study. Gastroenterology 2011; 140: S590.
169. Brandse JF, Vos LM, Jansen J, et al. Serum concentration of anti-TNF antibodies, adverse effects and quality of life in patients with inflammatory bowel disease in remission on maintenance treatment. J Crohn?s Colitis 2015; 9: 973-81. doi: 10.1093/ecco-jcc/jjv116.
170. Ungar B, Mazor Y, Weisshof R, et al. Induction infliximab levels among patients with acute severe ulcerative colitis compared with patients with moderately severe ulcerative colitis. Aliment Pharmacol Ther 2016; 43: 1293-9. doi: 10.1111/apt.13631.
171. Rosen MJ, Minar P, Vinks AA. Review article: applying pharmacokinetics to optimise dosing of anti-TNF biologics in acute severe ulcerative colitis. Aliment Pharmacol Ther 2015; 41: 1094-103. doi: 10.1111/apt.13175.
172. Herfarth HH, Rogler G, Higgins PD. Pushing the pedal to the metal: should we accelerate infliximab therapy for patients with severe ulcerative colitis?. Clin Gastroenterol Hepatol 2015; 13: 336-8. doi: 10.1016/j.cgh.2014.09.045.
173. Gibson DJ, Heetun ZS, Redmond CE, et al. An accelerated infliximab induction regimen reduces the need for early colectomy in patients with acute severe ulcerative colitis. Clin Gastroenterol Hepatol 2015; 13: 330-35.e1. doi: 10.1016/j.cgh.2014.07.041.
174. Laharie D, Bourreille A, Branche J, et al. Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. Lancet 2012; 380: 1909-15. doi: 10.1016/S0140-6736(12)61084-8.
175. Feuerstein JD, Cheifetz AS. Miscellaneous adverse events with biologic agents (excludes infection and malignancy). Gastroenterol Clin North Am 2014; 43: 543-63. doi: 10.1016/j.gtc.2014.05.002.
176. Moran GW, Lim AW, Bailey JL, et al. Review article: dermatological complications of immunosuppressive and anti-TNF therapy in inflammatory bowel disease. Aliment Pharmacol Ther 2013; 38: 1002-24. doi: 10.1111/.apt.12491.
177. Kaplan GG, Lim A, Seow CH, et al. Colectomy is a risk factor for venous thromboembolism in ulcerative colitis. World J Gastroenterol 2015; 21: 1251-60. doi: 10.3748/wjg.v21.i4.1251.
178. Mdlkfnen T, Wikstrfm A, Heiskanen K, et al. Skin reactions during anti-TNFα therapy for pediatric inflammatory bowel disease: a 2-year prospective study. Inflamm Bowel Dis 2014; 20: 1309-15. doi: 10.1097/.MIB.0000000000000088.
179. Fiorino G, Danese S, Pariente B, et al. Paradoxical immune-mediated inflammation in inflammatory bowel disease patients receiving anti-TNF-α agents. Autoimmun Rev 2014; 13: 15-9. doi: 10.1016/j.autrev.2013.06.005.
180. Cleynen I, Van Moerkercke W, Billiet T, et al. Characteristics of skin lesions associated with anti-Tumor necrosis factor therapy in patients with inflammatory bowel disease: a cohort study. Ann Intern Med 2016; 164: 10-22. doi: 10.7326/M15-0729.
181. Guerra I, Pérez-Jeldres T, Iborra M, et al. Incidence, clinical characteristics, and management of psoriasis induced by anti-TNF therapy in patients with inflammatory bowel disease: a nationwide cohort study. Inflamm Bowel Dis 2016; 22: 894-901. doi: 10.1097/MIB.0000000000000757.
182. Hellström AE, Färkkilä M, Kolho KL. Infliximab-induced skin manifestations in patients with inflammatory bowel disease. Scand J Gastroenterol 2016; 51: 563-71. doi: 10.3109/00365521.2015.1125524.
183. Kopylov U, Seidman E. Predicting durable response or resistance to antitumor necrosis factor therapy in inflammatory bowel disease. Therap Adv Gastroenterol 2016; 9: 513-26. doi: 10.1177/1756283X16638833.
184. Ma C, Huang V, Fedorak DK, et al. Outpatient ulcerative colitis primary anti-TNF responders receiving adalimumab or infliximab maintenance therapy have similar rates of secondary loss of response. J Clin Gastroenterol 2015; 49: 675-82. doi: 10.1097/MCG.0000000000000265.
185. Baert F, Kondragunta V, Lockton S, et al. Antibodies to adalimumab are associated with future inflammation in Crohn?s patients receiving maintenance adalimumab therapy: a post hoc analysis of the Karmiris trial. Gut 2016; 65: 1126-31. doi: 10.1136/gutjnl-2014-307882.
186. Benucci M, Li Gobbi F, Meacci F, et al. Antidrug antibodies against TNF-blocking agents: correlations between disease activity, hypersensitivity reactions, and different classes of immunoglobulins. Biologics 2015; 9: 7-12. doi: 10.2147/BTT.S69606.
187. García-Doval I, Hernández MV, Vanaclocha F, et al. Should TNF-Antagonists safety information be applied from patients with rheumatoid arthritis to psoriasis?. Rates of serious adverse events in the prospective rheumatoid arthritis Biobadaser and psoriasis Biobadaderm cohorts. Br J Dermatol 2017; 176: 643-9. doi: 10.1111/bjd.14776.
188. Steenholdt C, Svenson M, Bendtzen K, et al. Severe infusion reactions to infliximab: aetiology, immunogenicity and risk factors in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2011; 34: 51-8. doi: 10.1111/j.1365-2036.2011.04682.x.
189. Benucci M, Saviola G, Meacci F, et al. No correlations between the development of specific IgA and IgM antibodies againsTanti-TNF blocking agents, disease activity and adverse side reactions in patients with rheumatoid arthritis. Open Rheumatol J 2013; 7: 75-80. doi: 10.2174/1874 312901307010075.
190. Moss AC, Fernandez-Becker N, Jo Kim K, et al. The impact of infliximab infusion reactions on long-Term outcomes in patients with Crohn?s disease. Aliment Pharmacol Ther 2008; 28: 221-7. doi: 10.1111/j.1365-2036.2008.03734.x.
191. Bonovas S, Fiorino G, Allocca M, et al. Biologic therapies and risk of infection and malignancy in patients with inflammatory bowel disease: a systematic review and network meta-Analysis. Clin Gastroenterol Hepatol 2016; 14: 1385-97.e10. doi: 10.1016/j.cgh.2016.04.039.
192. Seror R, Mariette X. Malignancy and the risks of biologic therapies: current status. Rheum Dis Clin North Am 2017; 43: 43-64. doi: 10.1016/j.rdc.2016.09.006.
193. Raaschou P, Simard JF, Asker Hagelberg C, et al. Rheumatoid arthritis, anti-Tumour necrosis factor treatment, and risk of squamous cell and basal cell skin cancer: cohort study based on nationwide prospectively recorded data from Sweden. BMJ 2016; 352: i262doi: 10.1136/bmj.i262.
194. Scott FI, Mamtani R, Brensinger CM, et al. Risk of nonmelanoma skin cancer associated with the use of immunosuppressanTand biologic agents in patients with a history of autoimmune disease and nonmelanoma skin cancer. JAMA Dermatol 2016; 152: 164-72. doi: 10.1001/.jamadermatol.2015.3029.
195. Beaugerie L, Brousse N, Bouvier AM, et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet 2009; 374: 1617-25. doi: 10.1016/.S0140-6736(09)61302-7.
196. Khan N, Abbas AM, Lichtenstein GR, et al. Risk of lymphoma in patients with ulcerative colitis treated with thiopurines: a nationwide retrospective cohort study. Gastroenterology 2013; 145: 1007-15.e3. doi: 10.1053/j.gastro.2013.07.035.
197. Axelrad J, Bernheim O, Colombel JF, et al. Risk of new or recurrent cancer in patients with inflammatory bowel disease and previous cancer exposed to immunosuppressive and anti-Tumor necrosis factor agents. Clin Gastroenterol Hepatol 2016; 14: 58-64. doi: 10.1016/j.cgh.2015.07.037.
198. Shah ED, Farida JP, Siegel CA, et al. Risk for overall infection with anti-TNF and anti-integrin agents used in IBD: a systematic review and meta-Analysis. Inflamm Bowel Dis 2017; 23: 570-7. doi: 10.1097/.MIB.0000000000001049.
199. Billioud V, Ford AC, Tedesco ED, et al. Preoperative use of anti-TNF therapy and postoperative complications in inflammatory bowel diseases: a meta-Analysis. J Crohn?s Colitis 2013; 7: 853-67. doi: 10.1016/j.crohns.2013.01.014.
200. Narula N, Charleton D, Marshall JK. Meta-Analysis: peri-operative anti-TNFα treatmenTand post-operative complications in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2013; 37: 1057-64. doi: 10.1111/.apt.12313.
201. Kopylov U, Ben-Horin S, Zmora O, et al. Anti-Tumor necrosis factor and postoperative complications in Crohn?s disease: systematic review and meta-Analysis. Inflamm Bowel Dis 2012; 18: 2404-13. doi: 10.1002/.ibd.22954.
202. Selvaggi F, Pellino G, Canonico S, et al. Systematic review of cuff and pouch cancer in patients with ileal pelvic pouch for ulcerative colitis. Inflamm Bowel Dis 2014; 20: 1296-308. doi: 10.1097/MIB.0000000000000026.
203. Yang Z, Wu Q, Wang F, et al. Meta-Analysis: effect of preoperative infliximab use on early postoperative complications in patients with ulcerative colitis undergoing abdominal surgery. Aliment Pharmacol Ther 2012; 36: 922-8. doi: 10.1111/apt.12060.
204. Fumery M, Seksik P, Auzolle C, et al. Postoperative complications after ileocecal resection in Crohn?s disease: a prospective study from the REMIND Group. Am J Gastroenterol 2017; 112: 337-45. doi: 10.1038/ajg.2016.541.
205. Ng SW, Mahadevan U. Management of inflammatory bowel disease in pregnancy. Expert Rev Clin Immunol 2013; 9: 161-73, quiz 74. doi: 10.1586/.eci.12.103.
206. Poturoglu S, Ormeci AC, Duman AE. Treatment of pregnant women with a diagnosis of inflammatory bowel disease. World J Gastrointest Pharmacol Ther 2016; 7: 490-502. doi: 10.4292/wjgpt.v7.i4.490.
207. Mahadevan U, Martin CF, Chambers C, et al. Achievement of developmental milestones among offspring of women with inflammatory bowel disease: the PIANO Registry. Gastroenterology 2014; 146: S1. doi: 10.1016/S0016-5085(14)60001-9.
208. McConnell RA, Mahadevan U. Use of immunomodulators and biologics before, during, and after pregnancy. Inflamm Bowel Dis 2016; 22: 213-23. doi: 10.1097/MIB.0000000000000596.
209. Feagan BG, Greenberg GR, Wild G, et al. Treatment of active Crohn?s disease with MLN0002, a humanized antibody to the alpha4beta7 integrin. Clin Gastroenterol Hepatol 2008; 6: 1370-7. doi: 10.1016/j.cgh.2008.06.007.
210. Sandborn WJ, Feagan BG, Rutgeerts P, et al. Vedolizumab as induction and maintenance therapy for Crohn?s disease. N Engl J Med 2013; 369: 711-21. doi: 10.1056/NEJMoa1215739.
211. Varkas G, Thevissen K, De Brabanter G, et al. An induction or flare of arthritis and/or sacroiliitis by vedolizumab in inflammatory bowel disease: a case series. Ann Rheum Dis 2016; 76: 878-81. doi: 10.1136/.annrheumdis-2016-210233.
212. Hahn L, Beggs A, Wahaib K, et al. Vedolizumab: an integrin-receptor antagonist for treatment of Crohn?s disease and ulcerative colitis. Am J Health Syst Pharm 2015; 72: 1271-8. doi: 10.2146/ajhp140449.
213. Dulai PS, Singh S, Jiang X, et al. The real-world effectiveness and safety of vedolizumab for moderate-severe Crohn?s disease: results from the US VICTORY Consortium. Am J Gastroenterol 2016; 111: 1147-55. doi: 10.1038/ajg.2016.236.
214. Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2013; 369: 699-710. doi: 10.1056/NEJMoa1215734.
215. Colombel JF, Sands BE, Rutgeerts P, et al. The safety of vedolizumab for ulcerative colitis and Crohn?s disease. Gut 2017; 66: 839-51. doi: 10.1136/.gutjnl-2015-311079.
216. Parikh A, Fox I, Leach T, et al. Long-Term clinical experience with vedolizumab in patients with inflammatory bowel disease. Inflamm Bowel Dis 2013; 19: 1691-9. doi: 10.1097/MIB.0b013e318281f538.
217. Essat M, Tappenden P, Ren S, et al. Vedolizumab for the treatment of adults with moderate-To-severe active ulcerative colitis: an evidence review group perspective of a NICE single technology appraisal. Pharmacoeconomics 2016; 34: 245-57. doi: 10.1007/s40273-015-0334-3.
218. Arijs I, De Hertogh G, Lemmens B, et al. Effect of vedolizumab (anti-α4β7-integrin) therapy on histological healing and mucosal gene expression in patients with UC[published online first 7 Oct]. Gut 2016. doi: 10.1136/.gutjnl-2016-312293.
219. Bye WA, Jairath V, Travis SPL. Systematic review: the safety of vedolizumab for the treatment of inflammatory bowel disease[published online first: 27 Apr]. Aliment Pharmacol Ther 2017. doi: 10.1111/apt.14075.
220. Baumgart DC, Bokemeyer B, Drabik A, et al. Vedolizumab induction therapy for inflammatory bowel disease in clinical practice-A nationwide consecutive German cohort study. Aliment Pharmacol Ther 2016; 43: 1090-102. doi: 10.1111/apt.13594.
221. Sands BE, Feagan BG, Rutgeerts P, et al. Effects of vedolizumab induction therapy for patients with Crohn?s disease in whom tumor necrosis factor antagonist treatment failed. Gastroenterology 2014; 147: 618-27.e3. doi: 10.1053/j.gastro.2014.05.008.
222. Amiot A, Grimaud JC, Peyrin-Biroulet L, et al. Effectiveness and safety of vedolizumab induction therapy for patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2016; 14: 1593-1601.e2. doi: 10.1016/j.cgh.2016.02.016.
223. Rafia R, Scope A, Harnan S, et al. Vedolizumab for treating moderately to severely active Crohn?s disease after prior therapy: an evidence review group perspective of a NICE single technology appraisal. Pharmacoeconomics 2016; 34: 1241-53. doi: 10.1007/s40273-016-0436-6.
224. LeBlanc K, Mosli MH, Parker CE, et al. The impact of biological interventions for ulcerative colitis on health-related quality of life. Cochrane Database Syst Rev 2015; (9): CD008655. doi: 10.1002/14651858.CD008655.pub3.
225. Christensen B, Goeppinger SR, Colman RJ, et al. The efficacy and safety of calcineurin inhibitors in inducing and maintaining clinical remission in IBD patients commencing vedolizumab. Gastroenterology 2015; 148: S866.
226. Sands BE, Kozarek R, Spainhour J, et al. Safety and tolerability of concurrent natalizumab treatment for patients with Crohn?s disease not in remission while receiving infliximab. Inflamm Bowel Dis 2007; 13: 2-11. doi: 10.1002/.ibd.20014.
227. Hirten R, Longman RS, Bosworth BP, et al. Vedolizumab and infliximab combination therapy in the treatment of Crohn?s disease. Am J Gastroenterol 2015; 110: 1737-8. doi: 10.1038/ajg.2015.355.
228. McLean LP, Cross RK. Integrin antagonists as potential therapeutic options for the treatment of Crohn?s disease. Expert Opin Investig Drugs 2016; 25: 263-73. doi: 10.1517/13543784.2016.1148137.
229. Ben-Horin S, Casteele NV, Schreiber S, et al. Biosimilars in inflammatory bowel disease: facts and fears of extrapolation. Clin Gastroenterol Hepatol 2016; 14: 1685-96. doi: 10.1016/j.cgh.2016.05.023.
230. Ebbers HC, Chamberlain P. Controversies in establishing biosimilarity: extrapolation of indications and global labeling practices. BioDrugs 2016; 30: 1-8. doi: 10.1007/s40259-015-0154-1.
231. Reinisch W, Louis E, Danese S. The scientific and regulatory rationale for indication extrapolation: a case study based on the infliximab biosimilar CT-P13. Expert Rev Gastroenterol Hepatol 2015; 9(Suppl 1): 17-26. doi: 10.1 586/17474124.2015.1091306.
232. Park DI. Current status of biosimilars in the treatment of inflammatory bowel diseases. Intest Res 2016; 14: 15-20. doi: 10.5217/ir.2016.14.1.15.
233. Mantzaris GJ. Anti-TNFs: originators and biosimilars. Dig Dis 2016; 34: 132-9. doi: 10.1159/000443128.
234. Jahnsen J, Detlie TE, Vatn S, et al. Biosimilar infliximab (CT-P13) in the treatment of inflammatory bowel disease: a Norwegian observational study. Expert Rev Gastroenterol Hepatol 2015; 9(Suppl 1): 45-52. doi: 10.1586/17 474124.2015.1091308.
235. Smits LJ, Derikx LA, de Jong DJ, et al. Clinical outcomes following a switch from Remicade to the biosimilar CT-P13 in inflammatory bowel disease patients: a prospective observational cohort study. J Crohn?s Colitis 2016; 10: 1287-93. doi: 10.1093/ecco-jcc/jjw087.
236. Sieczkowska J, Jarzebicka D, Banaszkiewicz A, et al. Switching between infliximab originator and biosimilar in paediatric patients with inflammatory bowel disease. Preliminary observations. J Crohn?s Colitis 2016; 10: 127-32. doi: 10.1093/ecco-jcc/jjv233.
237. Schulze K, Koppka N, Lutter F, et al. CT-P13 (Inflectra, Remsima) monitoring in patients with inflammatory bowel disease. Biologicals 2016; 44: 463-6. doi: 10.1016/j.biologicals.2016.06.011.
238. Jha A, Upton A, Dunlop WC, et al. The budget impact of biosimilar infliximab (Remsima) for the treatment of autoimmune diseases in five European countries. Adv Ther 2015; 32: 742-56. doi: 10.1007/s12325-015-0233-1.
239. Danese S, Fiorino G, Michetti P. Changes in biosimilar knowledge among European Crohn?s Colitis Organization [ECCO] members: an updated survey. J Crohn?s Colitis 2016; 10: 1362-5. doi: 10.1093/ecco-jcc/jjw090.
240. Panaccione R, Sandborn WJ, Gordon GL, et al. Briakinumab for treatment of Crohn?s disease: results of a randomized trial. Inflamm Bowel Dis 2015; 21: 1329-40. doi: 10.1097/MIB.0000000000000366.
241. Alunno A, Carubbi F, Cafaro G, et al. Targeting the IL-23/IL-17 axis for the treatment of psoriasis and psoriatic arthritis. Expert Opin Biol Ther 2015; 15: 1727-37. doi: 10.1517/14712598.2015.1084284.
242. Simon EG, Ghosh S, Iacucci M, et al. Ustekinumab for the treatment of Crohn?s disease: can it find its niche?. Therap Adv Gastroenterol 2016; 9: 26-36. doi: 10.1177/1756283X15618130.
243. Hansen T, Targownik LE. Ustekinumab for the treatment of Crohn?s disease. Expert Rev Gastroenterol Hepatol 2016; 10: 989-94. doi: 10.1080/174741 24.2016.1215912.
244. Ma C, Fedorak RN, Kaplan GG, et al. Clinical, endoscopic and radiographic outcomes with ustekinumab in medically-refractory Crohn?s disease: real world experience from a multicentre cohort. Aliment Pharmacol Ther 2017; 45: 1232-43. doi: 10.1111/apt.14016.
245. Engel T, Kopylov U. Ustekinumab in Crohn?s disease: evidence to date and place in therapy. Ther Adv Chronic Dis 2016; 7: 208-14. doi: 10.1177/2040622316653306.
246. Sandborn WJ, Ghosh S, Panes J, et al. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N Engl J Med 2012; 367: 616-24. doi: 10.1056/NEJMoa1112168.
247. Archer TP, Moran GW, Ghosh S. Tofacitinib in ulcerative colitis. Immunotherapy 2016; 8: 495-502. doi: 10.2217/imt-2015-0031.
248. Sandborn WJ, Sands BE, D?Haens G, et al. Efficacy and safety of oral tofacitinib as induction therapy in patients with moderate-To-severe ulcerative colitis: results from 2 phase 3 randomised controlled trials. J Crohn?s Colitis 2016; 10: S157.
249. Sandborn WJ, Su C, Sands BE, et al. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2017; 376: 1723-36. doi: 10.1056/NEJMoa1606910.
250. Sandborn WJ, Ghosh S, Panes J, et al. A phase 2 study of tofacitinib, an oral Janus kinase inhibitor, in patients with Crohn?s disease. Clin Gastroenterol Hepatol 2014; 12: 1485-93.e2. doi: 10.1016/j.cgh.2014.01.029.
251. D?Haens G, Pannaccione R, Higgins PDR, et al. Efficacy and safety of oral tofacitinib for maintenance therapy in patients with moderate-To-severe Crohn?s disease: results of a phase 2b randomised placebo-controlled trial. J Crohn?s Colitis 2016; 10: S17-8doi: 10.1093/ecco-jcc/jjw019.020.
252. Vermeire S, Schreiber S, Petryka R, et al. Filgotinib, a selective JAK1 inhibitor, induces clinical remission in patients with moderate-To-severe Crohn?s disease: interim analysis from the phase 2 FITZROY study. J Crohn?s Colitis 2016; 10: S15-7.
253. Vermeire S, Schreiber S, Petryka R, et al. Clinical remission in patients with moderate-To-severe Crohn?s disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial. Lancet 2017; 389: 266-75. doi: 10.1016/S0140-6736(16)32537-5.
254. Sandborn WJ, Feagan BG, Wolf DC, et al. Ozanimod induction and maintenance treatment for ulcerative colitis. N Engl J Med 2016; 374: 1754-62. doi: 10.1056/NEJMoa1513248.
255. Monteleone G, Neurath MF, Ardizzone S, et al. Mongersen, an oral SMAD7 antisense oligonucleotide, and Crohn?s disease. N Engl J Med 2015; 372: 1104-13. doi: 10.1056/NEJMoa1407250.
256. Danese S, Fiorino G, Peyrin-Biroulet L. Targeting SMAD7 in Crohn?s disease by mongersen: therapeutic revolution under way?. Gastroenterology 2015; 149: 1121-3. doi: 10.1053/j.gastro.2015.08.023.
257. Kirchgesner J, Sokol H. Editorial: mongersen in Crohn?s disease-A new contribution to the beginning of a long-Awaited therapeutic revolution?. Aliment Pharmacol Ther 2016; 43: 838-9. doi: 10.1111/.apt.13563.